Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis

Chimeric Antigen Receptor (CAR) T cell therapy is an effective treatment approach for patients with relapsed or refractory acute lymphoblastic leukemia (R/R B-ALL). However, identifying the factors that influence long-term response to this therapy is necessary to optimize patient selection and treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Elsallab, Magdi, Ellithi, Moataz, Hempel, Susanne, Abdel-Azim, Hisham, Abou-el-Enein, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281866/
https://www.ncbi.nlm.nih.gov/pubmed/36750666
http://dx.doi.org/10.1038/s41417-023-00593-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281866/
https://www.ncbi.nlm.nih.gov/pubmed/36750666
http://dx.doi.org/10.1038/s41417-023-00593-3

Ejemplares similares